Cite
A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT)
MLA
Kenro Hirata, et al. “A Randomized Phase II Trial of Paclitaxel plus Ramucirumab versus Nab-Paclitaxel plus Ramucirumab for Gastric Cancer with Peritoneal Dissemination Refractory to First-Line Therapy (WJOG10617G/P-SELECT).” Journal of Clinical Oncology, vol. 40, Feb. 2022, p. 280. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8bdd9bccaa6f7ce8bb724df490d2753f&authtype=sso&custid=ns315887.
APA
Kenro Hirata, Yasuo Hamamoto, Hirokazu Shoji, Hiroki Hara, Chihiro Kondoh, Hisateru Yasui, Takeshi Kajiwara, Eishi Baba, Takayuki Ando, Naotoshi Sugimoto, Naohiro Okano, Hisato Kawakami, Hiroo Katsuya, Michitaka Nagase, Toshikazu Moriwaki, Kenichi Yoshimura, Masahiko Ando, Kentaro Yamazaki, Shuichi Hironaka, & Kei Muro. (2022). A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT). Journal of Clinical Oncology, 40, 280.
Chicago
Kenro Hirata, Yasuo Hamamoto, Hirokazu Shoji, Hiroki Hara, Chihiro Kondoh, Hisateru Yasui, Takeshi Kajiwara, et al. 2022. “A Randomized Phase II Trial of Paclitaxel plus Ramucirumab versus Nab-Paclitaxel plus Ramucirumab for Gastric Cancer with Peritoneal Dissemination Refractory to First-Line Therapy (WJOG10617G/P-SELECT).” Journal of Clinical Oncology 40 (February): 280. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8bdd9bccaa6f7ce8bb724df490d2753f&authtype=sso&custid=ns315887.